Neurogene (NGNE) Competitors $19.00 -1.08 (-5.38%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$19.20 +0.20 (+1.03%) As of 09/12/2025 07:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NGNE vs. STOK, ZYME, UPB, SION, ORIC, PHAR, SYRE, SPRY, PRAX, and QUREShould you be buying Neurogene stock or one of its competitors? The main competitors of Neurogene include Stoke Therapeutics (STOK), Zymeworks (ZYME), Upstream Bio (UPB), Sionna Therapeutics (SION), Oric Pharmaceuticals (ORIC), Pharming Group (PHAR), Spyre Therapeutics (SYRE), ARS Pharmaceuticals (SPRY), Praxis Precision Medicines (PRAX), and uniQure (QURE). These companies are all part of the "pharmaceutical products" industry. Neurogene vs. Its Competitors Stoke Therapeutics Zymeworks Upstream Bio Sionna Therapeutics Oric Pharmaceuticals Pharming Group Spyre Therapeutics ARS Pharmaceuticals Praxis Precision Medicines uniQure Stoke Therapeutics (NASDAQ:STOK) and Neurogene (NASDAQ:NGNE) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends, media sentiment and earnings. Does the media favor STOK or NGNE? In the previous week, Stoke Therapeutics had 8 more articles in the media than Neurogene. MarketBeat recorded 9 mentions for Stoke Therapeutics and 1 mentions for Neurogene. Neurogene's average media sentiment score of 1.85 beat Stoke Therapeutics' score of 1.20 indicating that Neurogene is being referred to more favorably in the news media. Company Overall Sentiment Stoke Therapeutics Positive Neurogene Very Positive Which has more risk & volatility, STOK or NGNE? Stoke Therapeutics has a beta of 1.14, suggesting that its stock price is 14% more volatile than the S&P 500. Comparatively, Neurogene has a beta of 1.58, suggesting that its stock price is 58% more volatile than the S&P 500. Do analysts prefer STOK or NGNE? Stoke Therapeutics currently has a consensus target price of $25.57, indicating a potential upside of 9.00%. Neurogene has a consensus target price of $46.17, indicating a potential upside of 142.98%. Given Neurogene's higher probable upside, analysts plainly believe Neurogene is more favorable than Stoke Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Stoke Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.22Neurogene 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75 Which has higher earnings and valuation, STOK or NGNE? Neurogene has lower revenue, but higher earnings than Stoke Therapeutics. Neurogene is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioStoke Therapeutics$36.56M35.16-$88.98M$0.8527.60Neurogene$930K291.54-$75.14M-$4.31-4.41 Do insiders & institutionals believe in STOK or NGNE? 52.4% of Neurogene shares are owned by institutional investors. 9.5% of Stoke Therapeutics shares are owned by insiders. Comparatively, 9.9% of Neurogene shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is STOK or NGNE more profitable? Stoke Therapeutics has a net margin of 26.25% compared to Neurogene's net margin of 0.00%. Stoke Therapeutics' return on equity of 18.32% beat Neurogene's return on equity.Company Net Margins Return on Equity Return on Assets Stoke Therapeutics26.25% 18.32% 15.48% Neurogene N/A -33.33%-30.34% SummaryStoke Therapeutics beats Neurogene on 10 of the 17 factors compared between the two stocks. Get Neurogene News Delivered to You Automatically Sign up to receive the latest news and ratings for NGNE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NGNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NGNE vs. The Competition Export to ExcelMetricNeurogeneMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$271.13M$3.15B$5.78B$10.18BDividend YieldN/A2.32%5.73%4.60%P/E Ratio-4.4121.5775.6326.02Price / Sales291.54254.90462.3591.38Price / CashN/A44.4425.8129.91Price / Book0.919.6112.766.25Net Income-$75.14M-$53.29M$3.29B$270.76M7 Day Performance-2.31%0.57%0.86%2.54%1 Month Performance-7.36%4.56%4.70%5.73%1 Year Performance-54.71%10.44%69.47%25.85% Neurogene Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NGNENeurogene1.9 of 5 stars$19.00-5.4%$46.17+143.0%-54.7%$271.13M$930K-4.4190Positive NewsSTOKStoke Therapeutics3.9294 of 5 stars$21.99+6.3%$25.57+16.3%+62.1%$1.13B$36.56M25.87100Positive NewsZYMEZymeworks0.0211 of 5 stars$15.19+0.9%N/AN/A$1.13B$76.30M-15.66460UPBUpstream Bio1.8338 of 5 stars$18.73-6.2%$56.50+201.7%N/A$1.08B$2.37M0.0038Positive NewsSIONSionna Therapeutics2.7945 of 5 stars$21.62-9.9%$38.00+75.8%N/A$1.06BN/A0.0035High Trading VolumeORICOric Pharmaceuticals4.5608 of 5 stars$10.50-3.5%$17.29+64.6%+9.0%$1.06BN/A-5.5680Positive NewsPHARPharming Group2.2355 of 5 stars$14.80-3.0%$30.00+102.7%+95.7%$1.05B$297.20M-113.85280News CoverageShort Interest ↑SYRESpyre Therapeutics2.2595 of 5 stars$16.63-2.2%$53.40+221.1%-46.7%$1.03B$890K-4.8973Positive NewsSPRYARS Pharmaceuticals2.5996 of 5 stars$10.70+6.3%$32.50+203.7%-24.6%$995.18M$89.15M-21.8490PRAXPraxis Precision Medicines2.2872 of 5 stars$40.75-13.0%$85.88+110.7%-37.0%$985.99M$8.55M-3.32110Positive NewsGap DownHigh Trading VolumeQUREuniQure3.214 of 5 stars$17.43-2.9%$37.45+114.9%+191.3%$984.86M$27.12M-4.45500 Related Companies and Tools Related Companies STOK Alternatives ZYME Alternatives UPB Alternatives SION Alternatives ORIC Alternatives PHAR Alternatives SYRE Alternatives SPRY Alternatives PRAX Alternatives QURE Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NGNE) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurogene Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurogene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NGNE Stock Alerts